Paul Nielsen, MD
Family Medicine · Wooster, OHNPI 1912187071
Payments from drug & device makers
Across 210 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Boehringer Ingelheim$281
- GSK$258
- Pfizer$204
- Astellas Pharma US Inc$196
- Lilly USA, LLC$185
- plus $1K from 33 others
What the payments were for
- Food & beverage$3,48898%
- Education$702%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 61 | $1,036 |
| Boehringer Ingelheim | 15 | $281 |
| GSK | 14 | $258 |
| Pfizer | 12 | $204 |
| Astellas Pharma US Inc | 11 | $196 |
| Lilly USA, LLC | 12 | $185 |
| Bayer | 10 | $150 |
| Xeris Pharmaceuticals, Inc. | 7 | $140 |
| Amarin Pharma, Inc. | 8 | $127 |
| Novo Nordisk | 6 | $96 |
| Merck | 6 | $94 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $62 |
| Johnson & Johnson | 4 | $56 |
| Novartis | 3 | $54 |
| Aimmune Therapeutics, Inc. | 3 | $50 |
| Sunovion Pharmaceuticals Inc. | 3 | $45 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Corcept Therapeutics | 2 | $39 |
| Nestle Healthcare Nutrition Inc. | 2 | $38 |
| Alkermes, Inc. | 2 | $33 |
| Edwards Lifesciences | 1 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $33 |
| Amgen | 2 | $32 |
| AstraZeneca | 2 | $29 |
| Corium, LLC | 1 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Exact Sciences | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Radius Health, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Cranial Technologies, Inc | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
| Urovant Sciences Inc | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Fidia Pharma USA Inc. | 1 | $10 |
How this compares
$3,558 in reported general payments places this provider in the 80th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 546 | $217,500 |
| JardianceEmpagliflozin | 169 | $130,125 |
| TrulicityDulaglutide | 91 | $101,356 |
| OzempicSemaglutide | 82 | $98,069 |
| FarxigaDapagliflozin Propanediol | 55 | $52,197 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $42,415 |
| CreonLipase/Protease/Amylase | 27 | $40,273 |
| XareltoRivaroxaban | 130 | $36,495 |
| RexultiBrexpiprazole | 24 | $32,725 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 345 | $26,439 |
| XifaxanRifaximin | 16 | $24,144 |
| Humalog Kwikpen U-100Insulin Lispro | 158 | $24,142 |
| GemtesaVibegron | 77 | $21,592 |
| LinzessLinaclotide | 29 | $20,437 |
| JanuviaSitagliptin Phosphate | 19 | $20,013 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $204 | $225,998573 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $281 | $140,139188 claims |
| Lilly USA, LLCTrulicity | $185 | $101,35691 claims |
| Novo NordiskOzempic | $96 | $98,06982 claims |
| AstraZenecaFarxiga, Brilinta | $29 | $62,315100 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $258 | $61,138105 claims |
| AbbVieCreon, Linzess | $1,036 | $60,71056 claims |
| MerckJanuvia, Janumet | $94 | $37,88933 claims |
| Johnson & JohnsonXarelto | $56 | $36,495130 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $23 | $32,72524 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $62 | $24,14416 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $23 | $21,59277 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Wooster
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.